In last trading session, Novavax, Inc (NASDAQ:NVAX) saw 3.58 million shares changing hands with its beta currently measuring 2.90. Company’s recent per share price level of $8.02 trading at -$0.23 or -2.79% at ring of the bell on the day assigns it a market valuation of $1.28B. That closing price of NVAX’s stock is at a discount of -197.51% from its 52-week high price of $23.86 and is indicating a premium of 52.49% from its 52-week low price of $3.81.

For Novavax, Inc (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.65 in the current quarter.

Novavax, Inc (NASDAQ:NVAX) trade information

Upright in the red during last session for losing -2.79%, in the last five days NVAX remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $8.02 price level, adding 6.09% to its value on the day. Novavax, Inc’s shares saw a change of -0.25% in year-to-date performance and have moved -0.74% in past 5-day. Novavax, Inc (NASDAQ:NVAX) showed a performance of -4.52% in past 30-days.

Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 63.55% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 25. It follows that stock’s current price would drop -74.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -74.56% for stock’s current value.

Novavax, Inc (NVAX) estimates and forecasts

This year revenue growth is estimated to fall -30.00% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 90.92M for the same. And 1 analysts are in estimates of company making revenue of 47.5M in the next quarter. Company posted 291.34M and 93.86M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.55% during past 5 years.

Novavax, Inc (NASDAQ:NVAX)’s Major holders

VANGUARD GROUP INC is the top institutional holder at NVAX for having 14.08 million shares of worth $178.19 million. And as of 2024-06-30, it was holding 10.0599 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 11.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.4669 of outstanding shares, having a total worth of $149.98 million.

On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 4.86 shares of worth $38.97 million or 3.03% of the total outstanding shares. The later fund manager was in possession of 4.1 shares on Nov 30, 2024 , making its stake of worth around $32.87 million in the company or a holder of 2.56% of company’s stock.